---
title: "Clinical Trial Reporting Standards"
description: "The International Council for Harmonisation (ICH) E3 guideline defines the structure and content of clinical study reports (CSRs) for regulatory submission."
type: skill
canonical_url: https://claudary.paisolsolutions.com/skills/clinical-trial-reporting
source: "Claudary"
difficulty: intermediate
author: "Claude Code Knowledge Pack"
date: 2026-07-10T11:14:05.443Z
license: CC-BY-4.0
attribution: "Clinical Trial Reporting Standards — Claudary (https://claudary.paisolsolutions.com/skills/clinical-trial-reporting)"
---

# Clinical Trial Reporting Standards
The International Council for Harmonisation (ICH) E3 guideline defines the structure and content of clinical study reports (CSRs) for regulatory submission.

## Overview

# Clinical Trial Reporting Standards

## ICH-E3: Structure and Content of Clinical Study Reports

The International Council for Harmonisation (ICH) E3 guideline defines the structure and content of clinical study reports (CSRs) for regulatory submission.

### CSR Overview

**Purpose:**
- Provide comprehensive description of study design, conduct, and results
- Support regulatory decision-making
- Document evidence of safety and efficacy

**Audience:**
- Regulatory authorities (FDA, EMA, PMDA, etc.)
- Medical reviewers
- Statistical reviewers
- Clinical pharmacology reviewers

**Length:** Typically 50-300 pages (main text), with extensive appendices

### Main Sections of ICH-E3 CSR

#### Section 1: Title Page

**Required elements:**
- Full study title
- Protocol number and version
- Sponsor name and address
- Compound/drug name and code
- Study phase
- Indication
- Report date and version number
- Report authors
- Confidentiality statement

#### Section 2: Synopsis

**Length:** 5-15 pages

**Content:**
- Brief summary of entire CSR
- Must be understandable as standalone document
- Cover all major sections

**Standard synopsis elements:**
1. Study identifier and title
2. Study objectives
3. Methodology:
   - Study design
   - Number and description of patients
   - Diagnosis and main criteria for inclusion
   - Study treatments
   - Duration of treatment
   - Criteria for evaluation
   - Statistical methods
4. Results:
   - Number of patients enrolled, completed, discontinued
   - Efficacy results
   - Safety results
5. Conclusions

#### Section 3: Ethics

**3.1 Independent Ethics Committee/Institutional Review Board**
- Names and locations of all IRBs
- Dates of initial approval
- Dates of protocol amendment approvals
- Documentation of continuing review

**3.2 Ethical Conduct of Study**
- Statement of compliance with GCP and Declaration of Helsinki
- Protocol adherence
- Informed consent process

**3.3 Patient Information and Consent**
- Description of informed consent procedures
- Consent form versions used
- Process for re-consent if applicable

#### Section 4: Investigators and Study Administrative Structure

**4.1 Investigators**
- List of principal investigators by site
- Site addresses and enrollment
- Coordinating investigator (if applicable)

**4.2 Administrative Structure**
- Sponsor personnel and roles
- CRO involvement (if applicable)
- Monitoring procedures
- Data management organization
- Statistical analysis organization

**4.3 Study Monitoring and Quality Assurance**
- Monitoring procedures and frequency
- Source document verification
- Quality control procedures
- Audits performed

#### Section 5: Introduction

**5.1 Background**
- Disease or condition being studied
- Current treatment landscape
- Unmet medical need

**5.2 Investigational Product**
- Pharmacology and mechanism of action
- Nonclinical findings
- Prior clinical experience
- Known safety profile

**5.3 Non-Investigational Therapy**
- Comparator drugs or placebo
- Concomitant medications allowed/prohibited

#### Section 6: Study Objectives

**6.1 Primary Objective**
- Main research question
- Clearly stated and specific
- Example: "To evaluate the efficacy of Drug X compared to placebo in reducing HbA1c in patients with type 2 diabetes mellitus over 24 weeks of treatment"

**6.2 Secondary Objectives**
- Additional research questions
- Supportive efficacy endpoints
- Safety objectives
- Exploratory objectives

**6.3 Endpoints**
- Primary endpoint definition and measurement
- Secondary endpoints
- Safety endpoints
- Pharmacokinetic endpoints (if applicable)
- Biomarker endpoints (if applicable)

#### Section 7: Investigational Plan

**7.1 Overall Study Design and Plan**
- Study design type (parallel, crossover, factorial, etc.)
- Randomization and blinding
- Study phases or periods
- Duration of treatment and follow-up
- Dosing regimen
- Study flow diagram (patient flowchart)

**7.2 Sample Size**
- Target enrollment
- Sample size justification
- Power calculation assumptions:
  - Expected effect size
  - Variability estimates
  - Type I error (alpha)
  - Power (1 - beta)
  - Drop-out rate assumptions

**7.3 Statistical Methods**
- Analysis populations (ITT, PP, safety)
- Handling of missing data
- Interim analyses (if planned)
- Multiplicity adjustments
- Subgroup analyses
- Sensitivity analyses

**7.4 Changes to Protocol**
- Protocol amendments and rationale
- Impact on study conduct and analysis

#### Section 8: Study Patients

**8.1 Inclusion and Exclusion Criteria**
- Key inclusion criteria
- Key exclusion criteria
- Rationale for criteria

**8.2 Demographic and Baseline Characteristics**
- Age, sex, race/ethnicity
- Disease severity or stage
- Prior therapies
- Baseline values of key endpoints
- Comparability across treatment groups

**8.3 Patient Disposition**
- Number screened
- Number randomized
- Number completing study
- Number withdrawn (by reason)
- Number lost to follow-up
- CONSORT flow diagram

**8.4 Protocol Deviations**
- Major protocol deviations
- Minor protocol deviations
- Impact on efficacy and safety analyses
- Corrective actions taken

**8.5 Demographic and Other Baseline Characteristics**
- Detailed demographic tables
- Baseline disease characteristics
- Stratification factors
- Medical history
- Prior/concomitant medications

#### Section 9: Efficacy Evaluation

**9.1 Data Sets Analyzed**
- Intent-to-treat (ITT) population
- Per-protocol (PP) population
- Modified ITT
- Other analysis sets
- Justification for population definitions

**9.2 Demographic and Baseline Characteristics**
- Demographics by analysis population
- Baseline comparability

**9.3 Measurements of Treatment Compliance**
- Drug accountability
- Pill counts or diary compliance
- Plasma drug levels (if measured)
- Percent of planned dose received

**9.4 Efficacy Results**

**9.4.1 Primary Endpoint**
- Results for primary endpoint
- Statistical analysis
- Effect size and confidence intervals
- P-values
- Subgroup analyses

**9.4.2 Secondary Endpoints**
- Results for each secondary endpoint
- Statistical analyses
- Hierarchy of testing (if applicable)

**9.4.3 Other Efficacy Endpoints**
- Exploratory endpoints
- Post-hoc analyses
- Responder analyses

**9.5 Dropouts and Missing Data**
- Patterns of missing data
- Reasons for dropout
- Sensitivity analyses for missing data

#### Section 10: Safety Evaluation

**10.1 Extent of Exposure**
- Duration of exposure
- Dose intensity
- Dose delays or reductions
- Treatment discontinuations due to adverse events

**10.2 Adverse Events**

**10.2.1 Overview of Adverse Events**
- Summary tables (any AE, treatment-related, serious, leading to discontinuation)
- Percentage of patients with AEs
- Comparison across treatment groups

**10.2.2 Common Adverse Events**
- AEs occurring in ≥5% or ≥10% of patients
- Sorted by frequency
- Preferred terms and system organ class (MedDRA)

**10.2.3 Serious Adverse Events**
- Definition of SAE
- Summary table of SAEs
- Individual narratives for each SAE
- Causality assessment
- Outcome

**10.2.4 Adverse Events Leading to Discontinuation**
- AEs leading to study drug discontinuation
- Frequency and type
- Relationship to study drug

**10.2.5 Deaths**
- All deaths during study and follow-up
- Detailed narratives for each death
- Relationship to study drug
- Autopsy findings (if available)

**10.3 Clinical Laboratory Evaluations**
- Laboratory abnormalities
- Shift tables (normal to abnormal, abnormal to normal)
- Mean changes from baseline
- Laboratory values meeting protocol-defined criteria
- Hepatotoxicity monitoring (if applicable)

**10.4 Vital Signs and Physical Findings**
- Vital signs (BP, HR, temperature, respiratory rate)
- Mean changes from baseline
- Clinically significant changes
- Physical examination findings

**10.5 ECG Evaluation**
- QTc interval changes
- Other ECG abnormalities
- Clinically significant ECG findings

**10.6 Special Safety Evaluations**
- Immunogenicity (for biologics)
- Pregnancy outcomes (if applicable)
- Abuse potential (if applicable)
- Withdrawal or rebound effects
- Dependency potential

#### Section 11: Discussion and Overall Conclusions

**11.1 Efficacy Discussion**
- Interpretation of efficacy results
- Clinical significance of findings
- Consistency with prior studies
- Limitations

**11.2 Safety Discussion**
- Safety profile overview
- Notable safety findings
- Comparison to known safety profile
- Risk-benefit assessment

**11.3 Benefit-Risk Assessment**
- Overall benefit-risk conclusion
- Subpopulations with favorable/unfavorable benefit-risk
- Implications for dosing or patient selection

**11.4 Clinical Implications**
- Place in therapy
- Target patient population
- Comparison to existing therapies

#### Section 12: Tables, Figures, and Graphs

Comprehensive set of tables and figures for efficacy and safety data.

**Common tables:**
- Demographic and baseline characteristics
- Patient disposition
- Extent of exposure
- Efficacy results (primary and secondary endpoints)
- Adverse event summary
- Common adverse events
- Serious adverse events
- Deaths
- Laboratory abnormalities
- Vital signs

**Common figures:**
- Study design schematic
- Patient disposition flowchart (CONSORT)
- Kaplan-Meier curves (survival, time to event)
- Forest plots (subgroup analyses)
- Mean change over time plots

#### Section 13: References

- Publications cited in CSR
- Relevant literature
- Regulatory guidelines
- Prior study reports

#### Section 14: Appendices

**Required appendices:**
- Study protocol and amendments
- Sample case report forms
- Investigator list with IRB information
- Patient information and informed consent forms
- List of patients receiving study drug
- Randomization scheme
- Audit certificates (if applicable)
- Documentation of statistical methods
- Publications based on study

**Optional appendices:**
- Individual patient data listings
- SAE narratives
- Laboratory normals and conversion factors
- Investigator signatures

### Statistical Analysis Plan (SAP)

**SAP Components:**
- Analysis populations
- Handling of missing data
- Statistical tests to be used
- Adjustment for multiplicity
- Interim analysis plan
- Subgroup analyses
- Sensitivity analyses
- Safety analyses

**SAP Timing:**
- Finalized before database lock
- Amendments documented with rationale

## CONSORT (Consolidated Standards of Reporting Trials)

CONSORT guidelines promote transparent and complete reporting of randomized controlled trials.

### CONSORT 2010 Checklist

#### Title and Abstract
- **1a. Title**: Identification as randomized trial in title
- **1b. Abstract**: Structured summary covering trial design, methods, results, conclusions

#### Introduction
- **2a. Background**: Scientific background and explanation of rationale
- **2b. Objectives**: Specific objectives or hypotheses

#### Methods - Participants
- **3a. Eligibility**: Eligibility criteria for participants
- **3b. Settings**: Settings and locations of data collection

#### Methods - Interventions
- **4a. Interventions**: Details of interventions for each group
- **4b. Details**: Sufficient details to allow replication

#### Methods - Outcomes
- **5. Outcomes**: Clearly defined primary and secondary outcome measures
- **6a. Sample size**: How sample size was determined
- **6b. Interim analyses**: When applicable, explanation of interim analyses

#### Methods - Randomization
- **7a. Sequence generation**: Method of random sequence generation
- **7b. Allocation concealment**: Mechanism of allocation concealment
- **8a. Implementation**: Who generated allocation, enrolled, and assigned participants
- **8b. Blinding**: Whether participants, care providers, outcome assessors were blinded

#### Methods - Statistical
- **9. Statistical methods**: Methods for primary and secondary outcomes
- **10. Additional analyses**: Subgroup or adjusted analyses

#### Results - Participant Flow
- **11a. Enrollment**: Numbers screened, randomized, allocated
- **11b. Losses and exclusions**: For each group, losses and exclusions after randomization
- **12. Recruitment**: Dates defining recruitment and follow-up periods
- **13a. Baseline**: Baseline demographic and clinical characteristics
- **13b. Baseline comparability**: Numbers analyzed in each group

#### Results - Outcomes and Estimation
- **14a. Outcomes**: For primary and secondary outcomes, results for each group
- **14b. Binary outcomes**: For binary outcomes, effect sizes and confidence intervals
- **15. Ancillary analyses**: Results of other analyses performed

#### Results - Harms
- **16. Harms**: All important harms or unintended effects in each group

#### Discussion
- **17a. Limitations**: Trial limitations, addressing biases, imprecision
- **17b. Generalizability**: Generalizability (external validity) of trial findings
- **18. Interpretation**: Interpretation consistent with results, balancing benefits and harms
- **19. Registration**: Registration number and name of trial registry
- **20. Protocol**: Where full trial protocol can be accessed
- **21. Funding**: Sources of funding, role of funders

### CONSORT Flow Diagram

Standard format showing patient flow through trial:
```
Assessed for eligibility (n=)
    ↓
Randomized (n=)
    ├─ Allocated to intervention (n=)
    │   ├─ Received intervention (n=)
    │   └─ Did not receive intervention (n=)
    │       Give reasons
    ├─ Allocated to control (n=)
    │   ├─ Received control (n=)
    │   └─ Did not receive control (n=)
    │       Give reasons
    ↓
Lost to follow-up (n=)
    Give reasons
Discontinued intervention (n=)
    Give reasons
    ↓
Analyzed (n=)
Excluded from analysis (n=)
    Give reasons
```

## Serious Adverse Event (SAE) Reporting

### Definition of Serious Adverse Event

An adverse event or suspected adverse reaction is considered serious if it:
- Results in death
- Is life-threatening
- Requires inpatient hospitalization or prolongation of existing hospitalization
- Results in persistent or significant disability/incapacity
- Is a congenital anomaly/birth defect
- Requires intervention to prevent permanent impairment or damage (device-related)
- Other medically important events (based on medical judgment)

### SAE Report Components

**1. Administrative Information**
- Report type (initial, follow-up, final)
- Report number
- Date of report
- Reporter information
- Sponsor information
- Study identifier (protocol number, NCT number)

**2. Patient Information (De-identified)**
- Subject ID or randomization number
- Initials (if permitted)
- Age or date of birth (year only)
- Sex
- Race/ethnicity
- Weight
- Height

**3. Study Information**
- Study phase (I, II, III, IV)
- Study design (randomized, open-label, etc.)
- Treatment arm or randomization
- Date of first study drug
- Date of last study drug

**4. Event Information**
- Reported term (verbatim)
- MedDRA preferred term
- System organ class
- Date of onset
- Time of onset (if relevant)
- Date of resolution (or ongoing)
- Dura

---

Source: [Claudary](https://claudary.paisolsolutions.com/skills/clinical-trial-reporting) · https://claudary.paisolsolutions.com